CSI Market
Sign In | Register

Mirum Pharmaceuticals Inc (MIRM) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access MIRM quarterly Cash Flow →
This cash flow overview for Mirum Pharmaceuticals Inc spans from Dec 31 2021 to Dec 31 2025, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-23.36
Depreciation & amortization24.24
Amortization of Other Assets1.74
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-8.45
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation71.42
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized-1.72
Operating Lease Right Of Use Asset Amortization-
Amortization Of Premium On Investments-
Increase Decrease In Operating Lease Right Of Use Asset-
Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities50.10
Non Cash Interest Expense On Revenue Interest Purchase Agreement-
Non Cash Lease Expense1.73
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements-
Change In Fair Value Of Contingent Liabilities Associated With Acquisition-
Inventory Reserves Under Operating Activity-
Inventory Reserves And Firm Purchase Commitment Losses Under Operating Activity2.89
Costs Recognized On Sale Of Acquired Inventory-
Tax Benefit Associated With An Acquisition-
Gain On Sale Of Priority Review Voucher Net-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable-48.06
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-5.76
Other Working Capital-5.66
Other Noncash Income (Expense)-1.40
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.90
Discontinued operations0.00
Net Cash flow from Operating Activities55.83
Investing Activities
Capital Expenditures-0.95
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities74.43
Short-term Investments Acq.0.00
Payments for Tenant Improvements0.00
Proceeds From Paydowns Of Investments-
Proceeds From Sale Of Priority Review Voucher Net-
Additions To Intangible Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-97.43
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-23.95
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock40.14
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-225.52
Payment Of Issuance Costs Related To The Revenue Interest Liability-
Proceeds Of Issuance Costs Related To The Revenue Interest Liability-
Proceeds From Revenue Interest Liability-
Repayment Of Revenue Interest-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations222.93
Operating Lease Payments2.59
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities40.14
Effect of exchange rate on cash flow3.22
Discontinued operations0.00
Free Cash Flow54.87
Total Cash Flow75.24
4 historic quarters locked

Sign in to unlock the full Mirum Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Mirum Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 25, 2026
  • Source: mirm-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001759425-26-000013

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License